Novartis AG
NVS
$119.09
$0.540.46%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.65B | 12.86B | 11.94B | 17.60B | 16.18B |
| Total Depreciation and Amortization | 3.64B | 3.59B | 3.60B | 1.92B | 2.07B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.77B | 4.03B | 3.89B | -1.25B | -984.00M |
| Change in Net Operating Assets | -1.27B | -1.49B | -1.81B | -2.30B | -2.20B |
| Cash from Operations | 20.79B | 19.00B | 17.62B | 15.97B | 15.07B |
| Capital Expenditure | -1.46B | -1.39B | -1.37B | -1.21B | -1.15B |
| Sale of Property, Plant, and Equipment | 59.00M | 95.00M | 86.00M | 203.00M | 253.00M |
| Cash Acquisitions | -2.15B | -3.78B | -4.02B | -3.60B | -6.99B |
| Divestitures | 156.00M | 141.00M | 107.00M | -59.00M | -64.00M |
| Other Investing Activities | -1.92B | -1.35B | -2.32B | -1.57B | -128.00M |
| Cash from Investing | -5.32B | -6.28B | -7.51B | -6.24B | -8.08B |
| Total Debt Issued | 5.05B | 7.24B | 7.91B | 8.48B | 4.81B |
| Total Debt Repaid | -2.99B | -4.53B | -3.52B | -3.37B | -4.92B |
| Issuance of Common Stock | 26.00M | 31.00M | 30.00M | 30.00M | 25.00M |
| Repurchase of Common Stock | -11.05B | -9.95B | -8.33B | -6.83B | -5.60B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -7.82B | -7.75B | -7.62B | -7.62B | -7.62B |
| Other Financing Activities | -363.00M | -173.00M | -207.00M | -40.00M | 3.50B |
| Cash from Financing | -17.14B | -15.13B | -11.74B | -9.35B | -9.80B |
| Foreign Exchange rate Adjustments | 424.00M | 8.00M | -298.00M | 176.00M | -166.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | 648.00M | 0.00 |
| Net Change in Cash | -1.25B | -2.40B | -1.93B | 1.20B | -2.98B |